Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/131793
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Morton, J.I. | - |
dc.contributor.author | McDonald, S.P. | - |
dc.contributor.author | Salim, A. | - |
dc.contributor.author | Liew, D. | - |
dc.contributor.author | Shaw, J.E. | - |
dc.contributor.author | Magliano, D.J. | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Diabetes Care, 2021; 44(7):1515-1523 | - |
dc.identifier.issn | 0149-5992 | - |
dc.identifier.issn | 1935-5548 | - |
dc.identifier.uri | http://hdl.handle.net/2440/131793 | - |
dc.description.abstract | Objective This study sought to examine the effects of two diabetes prevention approaches and of widespread use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) among people with diabetes on the future incidence of diabetes-related end-stage kidney disease (ESKD-D).<h4>Research design and methods</h4>We developed a life table model to project the incidence of ESKD-D for type 2 diabetes in Australia until 2040. We projected incident ESKD-D under three separate scenarios: a large-scale lifestyle modification program for diabetes prevention; a population-wide sugar-sweetened beverage tax for diabetes prevention; and widespread use of SGLT2is among people with diabetes.<h4>Results</h4>Assuming current trends, we projected that the annual incidence of ESKD-D will increase from 3.7 per 100,000 of the general population in 2014 to 5.7 by 2040. Incorporating the diabetes prevention approaches, we projected that the annual incidence of ESKD-D will be between 5.2 and 5.5 per 100,000 by 2040. When we modeled scenarios in which 50% and 70% of eligible people with diabetes were prescribed an SGLT2i, the annual incidence of ESKD-D by 2040 was projected to be 4.7 and 4.3 per 100,000, respectively. SGLT2is were projected to reduce the total number of incident ESKD-D cases between 2020 and 2040 by 12-21% compared with current trends, whereas diabetes prevention reduced cases by 1-3%.<h4>Conclusions</h4>It is likely that the number of people developing ESKD-D will increase over the coming decades, although widespread SGLT2i use will be effective at limiting this increase. Diabetes prevention will be crucial to prevent an ever-increasing burden of diabetes complications. | - |
dc.description.statementofresponsibility | Jedidiah I. Morton, Stephen P. McDonald, Agus Salim, Danny Liew, Jonathan E. Shaw and Dianna J. Magliano | - |
dc.language.iso | en | - |
dc.publisher | American Diabetes Association | - |
dc.rights | © 2021 by the American Diabetes Association | - |
dc.source.uri | http://dx.doi.org/10.2337/dc21-0220 | - |
dc.subject | Humans | - |
dc.subject | Kidney Failure, Chronic | - |
dc.subject | Diabetes Mellitus, Type 2 | - |
dc.subject | Incidence | - |
dc.subject | Forecasting | - |
dc.subject | Australia | - |
dc.title | Projecting the incidence of type 2 diabetes-related end-stage kidney disease until 2040: a comparison between the effects of diabetes prevention and the effects of diabetes treatment | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.2337/dc21-0220 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | McDonald, S.P. [0000-0001-6103-1386] | - |
dc.identifier.orcid | Liew, D. [0000-0002-0131-623X] | - |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.